Our top pick for
CorMedix Inc is a biotechnology business based in the US. CorMedix shares (CRMD) are listed on the NYSE and all prices are listed in US Dollars. CorMedix employs 30 staff and has a trailing 12-month revenue of around USD$174,806.
Since the stock market crash in March caused by coronavirus, CorMedix's share price has had significant negative movement.
Its last market close was USD$5.79, which is 9.39% down on its pre-crash value of USD$6.39 and 168.06% up on the lowest point reached during the March crash when the shares fell as low as USD$2.16.
If you had bought USD$1,000 worth of CorMedix shares at the start of February 2020, those shares would have been worth USD$405.56 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$847.71.
|Latest market close||USD$5.79|
|52-week range||USD$2.16 - USD$7.97|
|50-day moving average||USD$5.2489|
|200-day moving average||USD$4.9558|
|Wall St. target price||USD$15.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.644|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-17)||-3.82%|
|1 month (2020-10-23)||-1.03%|
|3 months (2020-08-25)||19.88%|
|6 months (2020-05-23)||N/A|
|1 year (2019-11-25)||-5.08%|
|2 years (2018-11-23)||332.09%|
|3 years (2017-11-24)||1,013.46%|
|5 years (2015-11-25)||151.74%|
|Gross profit TTM||USD$-89,968|
|Return on assets TTM||-60.53%|
|Return on equity TTM||-113.78%|
|Market capitalisation||USD$180.6 million|
TTM: trailing 12 months
There are currently 3.6 million CorMedix shares held short by investors – that's known as CorMedix's "short interest". This figure is 4.7% down from 3.7 million last month.
There are a few different ways that this level of interest in shorting CorMedix shares can be evaluated.
CorMedix's "short interest ratio" (SIR) is the quantity of CorMedix shares currently shorted divided by the average quantity of CorMedix shares traded daily (recently around 711863.14741036). CorMedix's SIR currently stands at 5.02. In other words for every 100,000 CorMedix shares traded daily on the market, roughly 5020 shares are currently held short.
However CorMedix's short interest can also be evaluated against the total number of CorMedix shares, or, against the total number of tradable CorMedix shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case CorMedix's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 CorMedix shares in existence, roughly 110 shares are currently held short) or 0.1165% of the tradable shares (for every 100,000 tradable CorMedix shares, roughly 117 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against CorMedix.
Find out more about how you can short CorMedix stock.
We're not expecting CorMedix to pay a dividend over the next 12 months.
CorMedix's shares were split on a 1:5 basis on 26 March 2019. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your CorMedix shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for CorMedix shares which in turn could have impacted CorMedix's share price.
Over the last 12 months, CorMedix's shares have ranged in value from as little as $2.16 up to $7.97. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while CorMedix's is 2.3988. This would suggest that CorMedix's shares are significantly more volatile than the average for this exchange and represent a higher risk.
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. It primarily focuses on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was founded in 2006 and is based in Berkeley Heights, New Jersey.
Steps to owning and managing SELF, with 24-hour and historical pricing before you buy.
Steps to owning and managing GLP, with 24-hour and historical pricing before you buy.
Steps to owning and managing FRGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing FSM, with 24-hour and historical pricing before you buy.
Steps to owning and managing EXFO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ESRT, with 24-hour and historical pricing before you buy.
Steps to owning and managing PLOW, with 24-hour and historical pricing before you buy.
Steps to owning and managing FOF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing CGNX, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.